10毫克、20毫克和30毫克剂量的H1组胺受体拮抗剂依巴斯汀以及10毫克曲普利啶对驾驶性能的急性和亚慢性影响。
Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance.
作者信息
Brookhuis K A, De Vries G, De Waard D
机构信息
Traffic Research Centre, University of Groningen, Haren, The Netherlands.
出版信息
Br J Clin Pharmacol. 1993 Jul;36(1):67-70. doi: 10.1111/j.1365-2125.1993.tb05894.x.
Abstract
- The effects of a new antihistamine, ebastine (10, 20 and 30 mg), on several parameters of driving performance in actual traffic were studied in 15 healthy male volunteers. Subjects were treated for 5 days, and their driving performance tested on day 1 and day 5. The study was double-blind, placebo controlled and included the antihistamine triprolidine (10 mg sustained release) as an active drug control. 2. General tolerability was good except in one case following the reference compound triprolidine. No significant changes in driving performance were found with the new antihistamine ebastine at any dosage, on day 1 or day 5. Triprolidine (10 mg) significantly increased both the amount of weaving and the delay in following speed manoeuvres of a leading car, compared with placebo. 3. The results suggest that ebastine in doses up to 30 mg may be relatively safe for use by those who drive motor vehicles while under medication. The results do not warrant such a conclusion for triprolidine 10 mg.
摘要
- 在15名健康男性志愿者中研究了一种新型抗组胺药依巴斯汀（10毫克、20毫克和30毫克）对实际交通中驾驶性能若干参数的影响。受试者接受治疗5天，并在第1天和第5天测试其驾驶性能。该研究为双盲、安慰剂对照研究，且将抗组胺药曲普利啶（10毫克缓释剂）作为活性药物对照。2. 总体耐受性良好，但在使用参比化合物曲普利啶后出现了1例例外情况。在第1天或第5天，新型抗组胺药依巴斯汀在任何剂量下均未发现驾驶性能有显著变化。与安慰剂相比，曲普利啶（10毫克）显著增加了车道变换次数以及跟随前车速度操作的延迟。3. 结果表明，剂量高达30毫克的依巴斯汀对于服药期间驾驶机动车的人而言可能相对安全。对于10毫克的曲普利啶，该结果并不支持这一结论。
相似文献
1
Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance.10毫克、20毫克和30毫克剂量的H1组胺受体拮抗剂依巴斯汀以及10毫克曲普利啶对驾驶性能的急性和亚慢性影响。
Br J Clin Pharmacol. 1993 Jul;36(1):67-70. doi: 10.1111/j.1365-2125.1993.tb05894.x.
2
3
Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine.抗组胺药依巴斯汀治疗不会增强地西泮对健康受试者行为的影响。
Br J Clin Pharmacol. 1993 Mar;35(3):272-7. doi: 10.1111/j.1365-2125.1993.tb05694.x.
4
Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.依巴斯汀速溶片（20毫克）与地氯雷他定胶囊（5毫克）对皮肤组胺反应抑制作用的比较：一项针对健康、非特应性成年人的随机、双盲、双模拟、安慰剂对照、三周期交叉研究。
Clin Ther. 2007 May;29(5):814-822. doi: 10.1016/j.clinthera.2007.05.001.
5
Effects of two antihistamine drugs on actual driving performance.两种抗组胺药物对实际驾驶性能的影响。
Br Med J (Clin Res Ed). 1984 Jan 28;288(6413):281-2. doi: 10.1136/bmj.288.6413.281.
6
Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects.依巴斯汀：一种新型抗组胺药对健康受试者精神运动表现和自主神经反应的影响。
Br J Clin Pharmacol. 1988 Nov;26(5):503-8. doi: 10.1111/j.1365-2125.1988.tb05289.x.
7
Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects.健康受试者中抗组胺药依巴斯汀与乙醇之间不存在药效学和药代动力学相互作用。
Eur J Clin Pharmacol. 1992;43(2):179-84. doi: 10.1007/BF01740667.
8
Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94.
Allergy. 1995 Mar;50(3):234-42. doi: 10.1111/j.1398-9995.1995.tb01140.x.
9
Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG.依巴斯汀和氯马斯汀对行为表现及脑电图急性效应的安慰剂对照比较
Eur J Clin Pharmacol. 1992;42(1):55-9. doi: 10.1007/BF00314920.
10
Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine.通过正电子发射断层扫描（PET）对人脑组胺H1受体占有率进行神经成像：第二代抗组胺药依巴斯汀与经典抗组胺药（+）-氯苯那敏的比较研究。
Br J Clin Pharmacol. 2001 Nov;52(5):501-9. doi: 10.1046/j.1365-2125.2001.01471.x.
引用本文的文献
1
EEG-Based Neurocognitive Metrics May Predict Simulated and On-Road Driving Performance in Older Drivers.基于脑电图的神经认知指标可能预测老年驾驶员的模拟驾驶和实际道路驾驶表现。
Front Hum Neurosci. 2019 Jan 15;12:532. doi: 10.3389/fnhum.2018.00532. eCollection 2018.
2
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.健康老年人睡前服用15毫克和30毫克苏沃雷生后次日上午的道路驾驶性能。
Psychopharmacology (Berl). 2016 Sep;233(18):3341-51. doi: 10.1007/s00213-016-4375-x. Epub 2016 Jul 16.
3
Central nervous system effects of the second-generation antihistamines marketed in Japan--review of inter-drug differences using the proportional impairment ratio (PIR)-.日本市场上第二代抗组胺药对中枢神经系统的影响——使用比例损伤率（PIR）对药物间差异的综述
PLoS One. 2014 Dec 12;9(12):e114336. doi: 10.1371/journal.pone.0114336. eCollection 2014.
4
Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines.依巴斯汀——基于 CONGA 推荐的第三代抗组胺药物研发
J Asthma Allergy. 2009 Aug 31;2:73-92. doi: 10.2147/jaa.s3108.
5
Impact of psychotropic medications on simulated driving: a critical review.精神药物对模拟驾驶的影响：一项批判性综述。
CNS Drugs. 2007;21(6):503-19. doi: 10.2165/00023210-200721060-00006.
6
Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.美喹他嗪、西替利嗪和右氯苯那敏对驾驶及精神运动表现的重复给药效应。
Br J Clin Pharmacol. 2006 Jan;61(1):79-86. doi: 10.1111/j.1365-2125.2005.02524.x.
7
Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements.地氯雷他定、苯海拉明和安慰剂对驾驶性能及精神运动性能测量的影响。
Eur J Clin Pharmacol. 2004 Jul;60(5):307-13. doi: 10.1007/s00228-004-0757-9. Epub 2004 May 28.
8
Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety.摇头丸（迷幻药）及多种药物联用对（模拟）驾驶性能和交通安全的影响。
Psychopharmacology (Berl). 2004 May;173(3-4):440-5. doi: 10.1007/s00213-003-1714-5. Epub 2004 Jan 9.
9
Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration.依巴斯汀和（+）-氯苯那敏对健康受试者认知功能的差异影响：认知障碍与血浆药物浓度之间的相关性。
Br J Clin Pharmacol. 2002 Mar;53(3):296-304. doi: 10.1046/j.0306-5251.2001.01183.x.
10
A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function.非索非那定、氯雷他定和异丙嗪对认知及精神运动功能影响的双盲、安慰剂对照研究
Br J Clin Pharmacol. 1999 Aug;48(2):200-6. doi: 10.1046/j.1365-2125.1999.00993.x.
本文引用的文献
1
2
Diazepam impairs lateral position control in highway driving.
Science. 1982 Jul 2;217(4554):79-81. doi: 10.1126/science.7089544.
3
Driving performance under the influence of drugs: rationale for, and application of, a new test.药物影响下的驾驶性能：一种新测试的原理及应用
Br J Clin Pharmacol. 1984;18 Suppl 1(Suppl 1):121S-129S. doi: 10.1111/j.1365-2125.1984.tb02590.x.
4
The H1-antagonist mequitazine: studies on performance and visual function.H1拮抗剂美喹他嗪：对行为表现和视觉功能的研究。
Eur J Clin Pharmacol. 1983;25(4):563-6. doi: 10.1007/BF00542129.
5
Effects of two antihistamine drugs on actual driving performance.两种抗组胺药物对实际驾驶性能的影响。
Br Med J (Clin Res Ed). 1984 Jan 28;288(6413):281-2. doi: 10.1136/bmj.288.6413.281.
6
Performance studies with the H1-histamine receptor antagonists, astemizole and terfenadine.使用H1组胺受体拮抗剂阿司咪唑和特非那定的性能研究。
Br J Clin Pharmacol. 1982 Feb;13(2):199-202. doi: 10.1111/j.1365-2125.1982.tb01356.x.
7
Studies on the central effects of the H1-antagonist, loratadine.
Eur J Clin Pharmacol. 1987;32(4):419-21. doi: 10.1007/BF00543979.
8
Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system.对SK&F 93944（替美斯汀）进行的药理学研究，SK&F 93944是一种新型组胺H1受体拮抗剂，穿透中枢神经系统的能力可忽略不计。
Br J Pharmacol. 1986 Mar;87(3):569-78. doi: 10.1111/j.1476-5381.1986.tb10199.x.
9
Repeated dose effects of lormetazepam and flurazepam upon driving performance.
Eur J Clin Pharmacol. 1990;39(1):83-7. doi: 10.1007/BF02657065.
10
Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG.依巴斯汀和氯马斯汀对行为表现及脑电图急性效应的安慰剂对照比较
Eur J Clin Pharmacol. 1992;42(1):55-9. doi: 10.1007/BF00314920.
Zotero 插件